Investor pushes Stallergenes to merge with U.S. partner; Polish drug market growing fast;

@FiercePharma: Pfizer shuttering vitamin C plant in California, 70 workers out of jobs. FiercePharmaManufacturing story | Follow @FiercePharma

@EricPFierce: UK starts on $85M cell manufacturing facility as report shows country has become net importer of drugs. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Merck's Rebif held its own in last year's MS market shakeup. What about 2015? More | Follow @CarlyHFierce

> The controlling shareholder in allergy drug specialist Stallergenes has proposed merging with its U.S. partner Greer to create a company with combined sales of €330 million, or about $368 million. Report

> The Polish drug market grew to €6.5 billion in 2014, with almost half of that spent on over-the-counter remedies. Report

> India's Sun Pharma bought GlaxoSmithKline's ($GSK) opiates business in Australia, a move that put Sun in charge of a quarter of the world's opiate supply, derived from poppies grown in the states of Tasmania and Victoria. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Nevro appoints former JJDC head to board as it awaits anticipated FDA approval. Article | Follow @FierceMedDev

@VarunSaxena2: FDA requires new labeling on insulin pens to ward off spread of infections. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: Pharma CMO? Meet your CIO--and start working together already. FiercePharmaMarketing article | Follow @EmilyWFierce

> Studies show need to supplement mammography with MRI, ultrasound for dense breast tissue. News

> Intuitive Surgical returns to the battlefield with $430M DOD contract. Article

> S&N falls on Stryker buyback plan, buys into Latin American distributor. Story

Biotech News

@FierceBiotech: Scripps investigators ID a key player in disarming chemotherapy. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers forges a billion-dollar cancer vaccine deal with Bavarian Nordic. News | Follow @JohnCFierce

@DamianFierce: Alkahest, a @JNJInnovation incuabatee, signed a $50M deal with Grifols. Release | Follow @DamianFierce

> Warp Drive recruits an Alnylam vet to take the reins. Item

> As split looms, Baxter bags autoimmune biotech SuppreMol for $225M. Story

> Startup Alkahest inks a $50M deal for anti-aging R&D. Article

> Genfit is next up in the M&A rumor mill thanks to its NASH drug. Report

Drug Delivery News

> Chrono Therapeutics ropes in new funds from Rock Health for smoking cessation device. Story

> Forbes gives drug delivery a shoutout, says it can make good drugs great. Item

> FDA requires new labeling on insulin pens to ward off spread of infections. Article

> Amgen launches delivery device for automatic administration of its blockbuster Neulasta. News

> Evidence that inhaled oxytocin improves social behavior among autistic patients spurs R&D. More

Diagnostics News

> FDA grants emergency use authorization to Corgenix's fast-acting Ebola diagnostic. Article

> RainDance waltzes toward $60M IPO. News

> Skin test could vastly simplify diagnosis of Alzheimer's and Parkinson's. More

> Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx. Story

> Vigilant Biosciences reels in $5.5M for oral cancer test. Report

Pharma Marketing News

> The long, strange story of Cubist's Cards Against Biotechnology. Feature

> Goldman cuts Afrezza sales forecast in half on slow uptake, pricing pressure. Report

> Surprise: Obesity med Contrave might help CV outcomes. Too bad Orexigen blabbed it. More

> The PD-1 wave? Report says it's a $33B tsunami, with BMS surfing for first place. Story

> Pharma CMO? Meet your CIO--and start working together already. Article

And Finally... Elderly people with cognitive problems may suffer faster decline if their blood pressure is too tightly controlled with drugs. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.